X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SAR443579 is an investigational trifunctional anti-CD123 NKp46xCD16 NK cell engager. It is being evaluated for relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia and high-risk myelodysplasia.
Lead Product(s): SAR443579
Therapeutic Area: Oncology Product Name: IPH6101
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2024
Details:
IPH6501 is, first-in-class antibody, CD20-targeting tetraspecific ANKET® that activates receptors (NKp46 and CD16) and the interleukin-2 receptor, it is being investigated in patients with Relapsed/Refractory CD20-expressing B-cell Non-Hodgkin’s Lymphoma.
Lead Product(s): IPH6501
Therapeutic Area: Oncology Product Name: IPH6501
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2024
Details:
IPH45, a preclinical stage, novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) targeting Nectin-4, which is being developed for tumors expressing Nectin-4.
Lead Product(s): IPH45
Therapeutic Area: Oncology Product Name: IPH45
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2024
Details:
IPH4102 (lacutamab) is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody which is currently in phase 2 clinical trials for treatment of cutaneous T-cell lymphoma (CTCL), an orphan disease, and peripheral T cell lymphoma (PTCL).
Lead Product(s): Lacutamab
Therapeutic Area: Oncology Product Name: IPH4102
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2024
Details:
Under the collaboration, Sanofi exercised one option to license a new ANKET® (antibody-based NK cell engager therapeutics) platform from Innate, for developing next-generation, multi-specific NK cell engagers to treat certain types of cancer.
Lead Product(s): Antibody-based NK Cell Engager Therapeutic
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Sanofi
Deal Size: $1,483.0 million Upfront Cash: $26.6 million
Deal Type: Licensing Agreement December 19, 2023
Details:
IPH4102 (lacutamab) is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody that is currently in clinical trials for treatment of cutaneous T-cell lymphoma (CTCL), an orphan disease, and peripheral T cell lymphoma (PTCL).
Lead Product(s): Lacutamab
Therapeutic Area: Oncology Product Name: IPH4102
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2023
Details:
SAR445514 / IPH6401 is a trifunctional anti-BCMA NKp46xCD16 NK cell engager, using Sanofi’s proprietary CROSSODILE® multi-functional platform, which comprises the Cross-Over-Dual-Variable-Domain format, which is investigated for Multiple Myeloma.
Lead Product(s): IPH6401
Therapeutic Area: Oncology Product Name: SAR445514
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 11, 2023
Details:
IPH5201 is a blocking antibody targeting the CD39 immunosuppressive pathway combination with durvalumab (anti-PD-L1) and chemotherapy, in treatment-naïve patients with resectable early stage non-small cell lung cancer (NSCLC).
Lead Product(s): IPH5201,Durvalumab,Carboplatin
Therapeutic Area: Oncology Product Name: IPH5201
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2023
Details:
SAR443579 (IPH6101) is the first NKp46/CD16-based NK cell engager using Innate’s proprietary multispecific antibody format ANKET™. It has shown anti-tumor activity for Hematological Malignancies.
Lead Product(s): IPH6101
Therapeutic Area: Oncology Product Name: SAR443579
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2023
Details:
Under the agreement, Takeda will obtain exclusive worldwide rights to develop, manufacture and commercialize Antibody Drug Conjugates (ADC) using a panel of selected antibodies developed by Innate with a primary focus in Celiac disease.
Lead Product(s): Antibody Drug Conjugate
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: $415.0 million Upfront Cash: $5.0 million
Deal Type: Licensing Agreement April 03, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
